Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Up 5.3% in January

Delcath Systems, Inc. (NASDAQ:DCTH) was the target of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 986,900 shares, a growth of 5.3% from the January 15th total of 937,100 shares. Based on an average daily trading volume, of 437,700 shares, the days-to-cover ratio is presently 2.3 days.

Institutional Trading of Delcath Systems

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Principal Financial Group Inc. acquired a new stake in Delcath Systems in the 3rd quarter worth $808,000. Baader Bank Aktiengesellschaft bought a new position in shares of Delcath Systems during the 4th quarter worth about $204,000. Barclays PLC bought a new position in shares of Delcath Systems during the 3rd quarter worth about $104,000. Jane Street Group LLC bought a new position in shares of Delcath Systems during the 3rd quarter worth about $110,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Delcath Systems by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 251,895 shares of the company’s stock worth $2,275,000 after acquiring an additional 7,298 shares during the period. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of Delcath Systems in a research note on Tuesday, January 14th. Craig Hallum raised their target price on shares of Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Friday, January 17th. Finally, StockNews.com upgraded shares of Delcath Systems from a “sell” rating to a “hold” rating in a research note on Friday, October 25th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.25.

Delcath Systems Stock Performance

NASDAQ DCTH opened at $16.37 on Wednesday. The company’s fifty day moving average is $13.77 and its two-hundred day moving average is $11.13. Delcath Systems has a 52-week low of $3.70 and a 52-week high of $16.97.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.